InsiderTrades.com logo
Philip Astley-Sparke net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Philip Astley-Sparke Biography and Net Worth

Chairman of Replimune Group

Philip Astley-Sparke is Executive Chairman and co-founder of Replimune and has served as a member of our Board since our formation in 2015. Previously he was the President and CEO of BioVex Inc, which developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Philip relocated the Company from the UK to the US in 2005 before Biovex was acquired by Amgen for up to $1bn in 2011. Subsequent to BioVex/Amgen, Philip was President at uniQure where he established their US infrastructure including the world’s largest gene therapy manufacturing facility and served as the Company’s Chairman from 2016 until June 2021. Philip also previously served as Chairman of the board of directors of Oxyrane Limited, a biotechnology company, from 2012 to 2020. Philip is currently a Venture Partner at Forbion Capital and serves on the board of Forbion European Acquisition Corp. Philip received a BSc in Cellular and Molecular Pathology from Bristol University UK, qualified as a Chartered Accountant with Arthur Andersen and was a healthcare investment banker with Robert Fleming / Chase H&Q.

What is Philip Astley-Sparke's net worth?

The estimated net worth of Philip Astley-Sparke is at least $11.14 million as of May 16th, 2024. Astley-Sparke owns 1,487,350 shares of Replimune Group stock worth more than $11,140,252 as of May 13th. This net worth evaluation does not reflect any other assets that Astley-Sparke may own. Additionally, Astley-Sparke receives a salary of $1,070,000.00 as Chairman at Replimune Group. Learn More about Philip Astley-Sparke's net worth.

How old is Philip Astley-Sparke?

Astley-Sparke is currently 53 years old. There are 7 older executives and no younger executives at Replimune Group. Learn More on Philip Astley-Sparke's age.

What is Philip Astley-Sparke's salary?

As the Chairman of Replimune Group, Inc., Astley-Sparke earns $1,070,000.00 per year. Learn More on Philip Astley-Sparke's salary.

How do I contact Philip Astley-Sparke?

The corporate mailing address for Astley-Sparke and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at ir@replimune.com. Learn More on Philip Astley-Sparke's contact information.

Has Philip Astley-Sparke been buying or selling shares of Replimune Group?

Philip Astley-Sparke has not been actively trading shares of Replimune Group over the course of the past ninety days. Most recently, Philip Astley-Sparke sold 37,928 shares of the business's stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a transaction totalling $245,394.16. Following the completion of the sale, the chairman now directly owns 1,487,350 shares of the company's stock, valued at $9,623,154.50. Learn More on Philip Astley-Sparke's trading history.

Who are Replimune Group's active insiders?

Replimune Group's insider roster includes Philip Astley-Sparke (Chairman), Robert Coffin (Insider), Pamela Esposito (Insider), Emily Hill (CFO), Colin Love (COO), Sushil Patel (CEO), Christopher Sarchi (Insider), Andrew Schwendenman (CAO), and Konstantinos Xynos (Chief Medical Officer). Learn More on Replimune Group's active insiders.

Are insiders buying or selling shares of Replimune Group?

During the last year, insiders at the sold shares 10 times. They sold a total of 133,782 shares worth more than $1,005,817.21. The most recent insider tranaction occured on December, 16th when CEO Sushil Patel sold 10,000 shares worth more than $124,200.00. Insiders at Replimune Group own 8.8% of the company. Learn More about insider trades at Replimune Group.

Information on this page was last updated on 12/16/2024.

Philip Astley-Sparke Insider Trading History at Replimune Group

See Full Table

Philip Astley-Sparke Buying and Selling Activity at Replimune Group

This chart shows Philip Astley-Sparke's buying and selling at Replimune Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Replimune Group Company Overview

Replimune Group logo
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $7.49
Low: $7.40
High: $7.95

50 Day Range

MA: $9.27
Low: $6.92
High: $12.11

2 Week Range

Now: $7.49
Low: $4.92
High: $17.00

Volume

441,099 shs

Average Volume

897,848 shs

Market Capitalization

$576.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68